HUMAN-PLATELET RESPONSE TO 3 SALICYLATE DOSAGE FORMS
HUMAN-PLATELET RESPONSE TO 3 SALICYLATE DOSAGE FORMS
复制标题
DOI：
10.1002/bdd.2510040107
复制
发表时间：
1983-01-01
影响因子：
2.1
通讯作者：
SPINO, M
中科院分区：
文献类型：
--
作者：
THIESSEN, JJ;GRAD, H;SPINO, M
用胶原诱导的14c - 5 -羟色胺释放评价乙酰水杨酸（ASA）对12名健康男性受试者血小板聚集的抑制作用。每位受试者接受单次口服剂量（650 mg）肠溶ASA （ecASA）和压缩ASA片（cASA），或ecASA和水杨酸钠（578 mg）至少间隔5周。高压液相色谱法测定血小板反应与血浆ASA和水杨酸有关。ecASA和cASA均抑制14c‐5 -羟色胺释放；两种产品的最大效果差异无统计学意义（p < 0.05）。观察到的最大血浆ASA水平与最大效果之间没有关系。此外，体内对14c‐5 -羟色胺释放的最大抑制与体外实验预测的释放之间没有相关性，体外实验是在含有特定ASA浓度的血浆中孵育后测量的。
Acetylsalicylic acid (ASA) inhibition of platelet aggregation as evaluated by collagen‐induced14C‐serotonin release, has been measured in 12 healthy male subjects. Each subject received a single oral dose (650 mg) of enteric‐coated ASA (ecASA) and compressed ASA tablets (cASA), or ecASA and sodium salicylate (578 mg) separated by a minimum of 5 weeks. The platelet response was related to plasma ASA and salicyclic acid determined by high‐pressure liquid chromatography. Both ecASA and cASA inhibited14C‐serotonin release; no significant difference was observed in the maximum effect between these two products (p> 0·05). No relationship was found between the maximum observed plasma ASA level and the maximum effect. Further, no correlation was found between the maximum inhibition of14C‐serotonin releasein vivoand the release predicted fromin vitroexperiments wherein the effect was measured after incubating plasma containing specified ASA concentrations.